<DOC>
	<DOCNO>NCT00551369</DOCNO>
	<brief_summary>RATIONALE : Stereotactic body radiation therapy may able send x-ray directly tumor cause less damage normal tissue near tumor . PURPOSE : This phase II trial study well stereotactic body radiation therapy work treat patient stage I stage II non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy Treating Patients With Stage I Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether treatment radiotherapy involve high biological dose limited treatment volume ( use stereotactic body radiotherapy [ SBRT ] technique ) achieve acceptable primary tumor control ( i.e. , ≥ 90 % 2 year ) patient resectable early-stage non-small cell lung cancer . Secondary - Determine whether treatment radiotherapy involve high biological dose limited treatment volume ( use SBRT technique ) achieve acceptable treatment-related toxicity . - Estimate disease-free survival overall survival rate 2 year . - Observe pattern failure first 2 year . - Assess level comorbidity burden morbidity efficacy . - Determine blood marker prior , course treatment ( second last dose SBRT ) , first follow-up SBRT predict 2-year primary tumor control predict grade ≥ 2 treatment-related toxicity OUTLINE : This multicenter study . Patients receive 3 fraction stereotactic body radiotherapy 14 day . Patients disease progression undergo surgical resection salvage local therapy . After completion study therapy , patient follow every 3 month 2 year , every 6 month 3 year annually thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer , include follow primary tumor type : Squamous cell carcinoma Adenocarcinoma Large cell carcinoma Large cell neuroendocrine tumor Nonsmall cell carcinoma otherwise specify No pure type bronchoalveolar cell carcinoma Stage I II disease base 1 follow combination primary tumor , regional node , metastasis ( TNM ) staging : T1 , N0 , M0 T2 ( ≤ 5 cm ) , N0 , M0 T3 ( ≤ 5 cm ) , N0 , M0 ( chest wall primary tumor ) No T2 T3 primary tumor &gt; 5 cm T3 primary tumor involve central chest structure mediastinum No primary tumor Tstage within touch zone proximal bronchial tree , define volume 2 cm direction around proximal bronchial tree ( carina , right leave main bronchus , right leave upper lobe bronchus , intermedius bronchus , right middle lobe bronchus , lingular bronchus , right leave low lobe bronchus ) Patients hilar mediastinal lymph node ≤ 1 cm AND abnormal hilar mediastinal uptake positron emission tomography ( PET ) scan consider N0 Patients &gt; 1 cm hilar mediastinal lymph node CT scan OR abnormal PET scan ( include suspicious nondiagnostic uptake ) still eligible directed tissue biopsy abnormally identify area negative cancer No direct evidence regional distant metastasis appropriate stag study Considered reasonable candidate surgical resection primary tumor , accord follow criterion : Primary tumor predict technically resectable high likelihood negative surgical margin ( determine qualify thoracic surgeon ) Baseline force expiratory volume ( FEV ) _1 &gt; 35 % predict Postoperative predict FEV_1 &gt; 30 % predicted Diffusion capacity &gt; 35 % predict No hypoxemia ( e.g. , partial pressure arterial oxygen ( PaO2 ) ≤ 60 mm Hg ) and/or hypercapnia ( e.g. , partial pressure arterial carbon dioxide ( PaCO2 ) &gt; 50 mm Hg ) baseline No severe pulmonary hypertension No severe cerebral , cardiac , peripheral vascular disease No severe chronic heart disease Pleural effusion , present , must deem small tap CT scan guidance must evident chest xray Pleural effusion appear chest xray allow thoracotomy invasive procedure PATIENT CHARACTERISTICS : Zubrod performance status 01 Absolute neutrophil count ≥ 1,800/mm³ Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No synchronous primary invasive malignancy within past 3 year nonmelanoma skin cancer situ cancer No active systemic , pulmonary , pericardial infection No weight loss &gt; 5 % reason within past 3 month PRIOR CONCURRENT THERAPY : No prior radiotherapy lung cancer Prior radiotherapy part treatment head neck cancer , breast cancer , nonlung cancer allow provide significant overlap stereotactic body radiotherapy field No prior chemotherapy surgical resection lung cancer No concurrent local regional antineoplastic therapy ( include standard fractionate radiotherapy , nonapproved systemic therapy , surgery ) , except disease progression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>